Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Deferoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | GAA | P10253 | 1/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.95 |
| ▸ | KDM4A | O75164 | 8/20 | 0.92 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.92 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.92 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.92 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.38 |
| ▸ | CASP2 | P42575 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deferoxamine SCHEMBL9555338 | 0.99 | KDM4E (0.93) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL1699778 | 0.97 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL7715593 | 0.97 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| SCHEMBL30036991 | 0.97 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL119982 | 0.97 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL3953046 | 0.96 | KDM4E (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL9351925 | 0.96 | KDM4E (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL34571 | 0.96 | KDM4A (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| SCHEMBL21051754 | 0.96 | KDM4A (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| SCHEMBL17100575 | 0.96 | KDM4A (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492158-B2 | Electrochemical labels derived from siderophores | APPLIED BIOSYSTEMS, LLC (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2276853-A2 | ELECTROCHEMICAL LABELS DERIVED FROM SIDEROPHORES | Life Technologies Corporation (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009134570-A2 | ELECTROCHEMICAL LABELS DERIVED FROM SIDEROPHORES | Life Technologies Corporation (US) | 2009-11-05 | — | — | WO | disclosed |
| US-20090246763-A1 | ELECTROCHEMICAL LABELS DERIVED FROM SIDEROPHORES | APPLERA CORPORATION, APPLIED BIOSYSTEMS GROUP (US) | 2009-10-01 | — | — | US | disclosed |
| US-5374771-A | Process for the preparation of high-purity deferoxamine salts | BIOGAL GYOGYSZERGYAR RT. (HU) | 1994-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246763-A1 | ELECTROCHEMICAL LABELS DERIVED FROM SIDEROPHORES | POLRMT, TFAM, NDUFS7 | KDM4E 4084/4885LMNA 2304/4885GAA 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.